Tumour micrometastases: The influence of angiogenesis

European Journal of Surgical Oncology

Volumn 26, Issue 2, 2000, Pages 105-115

  McDonnell, C O ^a   Hill, A D K ^a   McNamara, D A ^a   Walsh, T N ^a   Bouchier Hayes, D J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Angiogenesis; Metastasis

Indexed keywords

ANGIOGENESIS; CANCER; CANCER STAGING; DIAGNOSTIC VALUE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0034054526     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1999.0753     Document Type: Review

References (174)

1. thG.H.A. Clowes Memorial Award Lecture. Cancer Res. 50:1990;6130-6138.
2. Fidler IJ. Cancer metastases. Br Med Bull. 47:1991;157-177.
3. 125I-5-Iodo-2-Deoxyuridine. J Natl Cancer Inst. 45:1970;773-782.
4. Saphir O, Amromin GD. Obscure axillary lymph node metastasis in carcinoma of the breast. Cancer. 1:1948;238-241.
5. Huvos AG, Hutter R, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg. 173:1971;44-46.
6. Rosen PP, Saigo P, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer: prognostic significance of tumour size. Ann Surg. 194:1981;585-591.
7. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node microÍmetastases from breast carcinoma - reviewing the dilemma. Cancer. 80:1997;1188-1197.
8. Black RB, Roberts M, Stewart HJ. The search for occult metastases in breast cancer: does it add to established staging methods. Aust NZ J Surg. 50:1980;574-579.
9. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer. 42:1978;2025-2031.
10. Pickren JW. Significance of occult metastases. A study of breast cancer. Cancer. 14:1961;1266-1271.
11. Attiyeh FF, Jensen M, Huvos AG, Fracchia A. Axillary microÍmetastases and macrometastases in carcinoma of the breast. Surg Gynaecol Obst. 144:1977;839-842.
12. Hainsworth PJ, Tjandra J, Stillwell RG. Detection and significance of occult metastases in node negative breast cancer. Br J Surg. 80:1993;459-463.
13. Fisher ER, Palekar A, Rockette H, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (Protocol #4) V. Significance of axillary and nodall micro- and macrometastases. Cancer. 42:1978;2032-2038.
14. Friedman S, Bertin F, Mourisse H. Importance of tumour cells in axillary node sinus margins (clandestine metastases) discovered by serial sectioning in operable breast cancer. Acta Oncol. 27:1988;483-487.
15. Neville AM, Price K, Gelber RD, Goldhirsch A. Axillary node microÍmetastases and breast cancer. Lancet. 337:1991;110.
16. Chen Z-L, Wen D-L, Coulson WF, Giuliano AE, Cochran AJ. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histological examination and conventional histology. Dis Markers. 9:1991;239-248.
17. de Mascarel I, Binichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary node microÍmetastases assessed by two special techniques: re-evaluation with longer follow-up. Br J Cancer. 66:1992;523-527.
18. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node positive breast carcinomas. Cancer. 71:1993;1780-1790.
19. Nasser IA, Lee A, Bosari S, Saganich R, Heatley G, Silverman ML. Occult axillary lymph node metastases in ««node negative»» breast carcinoma. Hum Pathol. 24:1993;950-957.
20. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer; their detection and prognostic significance. Br J Cancer. 73:1996;88-95.
21. Trojani M, De Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of the breast. Br J Cancer. 55:1987;303-306.
22. Rosen PP, Saigo P, Blaun DW, Weathers E, Kinne DW. Prognosis in Stage II (T1N1M0). Breast Cancer Ann Surg. 194:1981;576-584.
23. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node microÍmetastases from breast cancers. Lancet. 335:1990;1565-1568.
24. Sedmak DD, Meineke TA, Knechtges DS, Anderson J. Prognostic significance of cytokeratin positive breast cancer metastases. Mod Pathol. 2:1989;516-520.
25. Gerber B, Krause A, Reime T. Immunohistochemically detected lymph node microÍmetastases in breast cancer and their correlation with prognostic factors. Breast J. 3:1997;106-111.
26. Schoenfeld A, Luqmani Y, Smith D. Detection of breast cancer microÍmetastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 54:1994;2986-2990.
27. Noguchi S, Aihara T, Nakamori S. The detection of breast carcinoma microÍmetastases in axillary lymph nodes by means of reverse transcriptase polymerase chain reaction. Cancer. 74:1994;1595-1600.
28. Noguchi S, Aihara T, Motumura K. Detection of breast cancer microÍmetastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol. 148:1996;649-656.
29. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of microÍmetastases and circulating tumour cells. Cancer Chemother Pharmacol. 38:1996;969-977.
30. Cutait R, Alves VAF, Lopes LC. Restaging of colorectal cancer based on the identification of lymph node micro- metastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum. 34:1991;817-820.
31. Adell G, Boery D, Franlund B, Sjodahl R, Hakansson L. Occurrence and prognostic importance of microÍmetastases in regional lymph nodes in Dukes B colorectal carcinoma - an immunohistochemical study. Eur J Surg. 162:1996;637-642.
32. Jeffers MD, O'Dowd GM, Mulcahy H. The prognostic significance of immunohistochemically detected lymph node microÍmetastases in colorectal cancer. J Pathol. 172:1994;183-187.
33. Liefers GJ, Cleton-Jansen AM, Van De Velde CJH, Herman J, Van Krieken JHJM, Cornelisse CJ, Tollenaar RAEM. Micrometastases and survival in Stage II Colorectal Carcinoma. N Eng J Med. 339:1998;223-228.
34. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 39:1977;456-466.
35. Morton DL, Wen D-R, Wong JH. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 127:1992;392-399.
36. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 220:1994;391-401.
37. Cox CE, Pendas S, Cox JM. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 227:1998;645-653.
38. Giuliano AE. Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine axillary dissection. J Surg Oncol. 62:1996;75-77.
39. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 222:1995;394-401.
40. Wang X, Heller R, VanVoorhis N. Detection of sub-microscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 220:1994;768-774.
41. Shivers SC, Wang X, Weiguo L. Molecular staging of malignant melanoma. JAMA. 280:1998;1410-1415.
42. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in the bone marrow of colorectal cancer patients. Lancet. 340:1992;685-689.
43. Cote RJ, Rosen PP, Old LJ, Osborne MP. Detection of bone marrow microÍmetastases in patients with early stage breast cancer. Diagn Oncol. 1:1991;37-42.
44. Cote RJ, Rosen PP, Lesser ML. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow microÍmetastases. J Clin Oncol. 9:1991;1749-1756.
45. Mansi JL, Berger M, Easton D. Micrometastases in the bone marrow in patients with primary breast cancer: evaluation of an early predictor of bone metastases. Br Med J. 295:1987;1093-1096.
46. Dearnaley DP, Ormerod MG, Sloane JP. Micrometastases in breast cancer: long term follow up of the first patient cohort. Eur J Cancer. 27:1991;236-239.
47. Diel IJ, Kaufmann M, Goerner R. Detection of tumour cells in the bone marrow of patients with primary breast cancer: a prognostic factor for distant metastases. J Clin Oncol. 10:1992;1534-1539.
48. Schlimok G, Funze I, Holzman B. Micrometastatic cancer cells in the bone marrow: in vitro detection with anti-cytokeratin and in vivo labelling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA. 84:1987;8672-8677.
49. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;571-573.
50. Menard S, Squicciarini P, Luini A, Sacchini V, Rovini P, Tagliabue E, Veronesi P, Salvadori B, Veronesi U, Colnaghi MI. Immunodetection of bone marrow microÍmetastases in breast cancer patients and its correlation with primary tumour prognostic features. Br J Cancer. 69:1994;1126-1129.
51. Cote RJ, Beattie EJ, Caiwun B, Shi S-R, Harvey J, Chen S-C. Detection of occult bone marrow microÍmetastases in patients with operable lung carcinoma. Ann Surg. 222:1995;415-425.
52. Schlimok G, Riethmuller G. Detection, characterisation and tumour genicity of disseminated tumour cells in human bone marrow. Semin Cancer Biol. 1:1990;207-215.
53. Diel IJ, Kaufman M, Costa SD. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 88:1996;1652-1664.
54. Pantel K, Braun S, Schlimok G, Riethmuller G. Micrometastatic tumour cells in the bone marrow in colorectal cancer. Lancet. 341:1993;501 (letter).
55. Schlimok G, Funke I, Bock B. Epithelial tumour cells in the bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterisation and prognostic significance. J Clin Oncol. 8:1990;831-837.
56. Maehera Y, Yamamoto M, Oda S, Baba H, Kusomoto T, Ohno S, Ichiyoshi Y, Sugimachi K. Cytokeratin positive cells in the bone marrow for identifying distant microÍmetastases of gastric carcinoma. Br J Cancer. 73:1996;83-87.
57. Wood DP, Banki ER, Humphreys S, McRoberts JW, Rangnekar V. Identification of bone marrow microÍmetastases in patients with prostatic carcinoma. Cancer. 74:1994;2533-2540.
58. O'Sullivan GC, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, Walsh T, Collins JK, Shanahan F. Micrometastases in esophagogastric cancer: High detection rate in resected rib segments. Gastroenterology. 116:1999;543-548.
59. Richard JC, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow microÍmetastases. J Clin Oncol. 9:1991;1744-1756.
60. Osborne MP, Wong GY, Asina S, Old CJ, Rosen PP. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res. 51:1991;2706-2709.
61. Osborne MP, Rosen PP. Detection and management of bone marrow microÍmetastases in breast cancer. Oncology. 8:1994;25-31.
62. Funke I, Fries S, Rolle M. Comparative analyses of bone marrow microÍmetastases in breast and gastric cancer. Int J Cancer. 65:1996;755-761.
63. Schlimok G, Funke I, Pantel K. Mircrometastatic tumour cells in the bone marrow of patients with gastric carcinoma: methodological aspects of detection and prognostic significance. Eur J Cancer. 27:1991;1461-1465.
64. Dorudi S, Kinrade E, Marshall NC. Genetic detection of lymph node microÍmetastases in patients with colorectal cancer. Br J Surg. 85:1998;98-100.
65. Folkman, J, Tumour Angiogenesis. Ed: Holland J, Frei E, Bast RC, et al., Cancer Medicine, IV Edn. Melbourne: Lea & Febinger 1991; 153, 71.
66. Gasparini G. Quantification of intratumoural vascularisation predicts metastases in human invasive solid tumours. Oncol Rep. 1:1994;7-12.
67. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst. 82:1990;4-6.
68. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumours. Ann Surg. 175:1972;409-416.
69. Folkman J, Cole P, Zimmerman S. Tumour behaviour in isolated perfused organs: in vitro growth and metastasis of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg. 164:1966;491-502.
70. Liotta LA, Steeg PS, Stetter-Stevenson WG. Cancer metastases and angiogenesis: an imbalance of positive and negative regulation. Cell. 64:1991;327-336.
71. Fidler IJ, Ellis LM. Implications of angiogenesis for the biology and therapy of cancer metastass. Cell. 79:1994;185-188.
72. Nagy JA, Brown LF, Senger DR. Pathogenesis of tumour stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochem Biophys Acta. 948:1989;305-326.
73. Moscatelli D, Gross JL, Rifun DB. Angiogenic factors stimulate plasminogen activator and collagenase production by capillary endothelial cells. J Cell Biol. 91:1981;201a.
74. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Ann Rev Physiol. 53:1991;217-239.
75. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumours: regulation of angiogenesis. J Leukoc Biol. 56:1994;423-435.
76. Bicknell R, Harris AL. Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol. 8:1996;60-65.
77. Bouck N, Stellmach V, Hsu SC. How tumours become angiogenic. Adv Cancer Res. 69:1996;135-174.
78. Folkman J, D'Amore PA. Blood vessel formation, what is its molecular basis? Cell. 87:1996;1153-1155.
79. Pluda JM. Tumour associated angiogenesis: mechanisms, clinical implications and therapeutic strategies. Semin Oncol. 24:1997;203-218.
80. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
81. Smith-McClune KK, Weidner N. Demonstration and char- acterÍisation of the anti-angiogenic properties of cervical dysplasia. Cancer Res. 54:1994;800-804.
82. Stellmach V, Volpert OV, Crawford SE, Lawler J, Hynes RO, Bouck N. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. Eur J Cancer. 32A:1996;2394-2400.
83. Bouck N. P53 and angiogenesis. Biochem Biophys Acta. 1287:1996;63-66.
84. Volpert OV, Dameron KM, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumourigenicity in vitro. Oncogene. 14:1997;1495-1502.
85. Folkman J. Angiogenesis inhibitors generated by tumours. Mol Med. 1:1995;120-122.
86. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nature Med. 1:1995;27-31.
87. Dameron KM, Volpert OV. Control of angiogenesis in fibroblasts by regulation of thrombospondin-1. Science. 265:1994;1582-1585.
88. Polverini PJ. How the extracellular matrix and macrophages contribute to angiogenesis dependent diseases. Eur J Cancer. 32A:1996;2430-2437.
89. Folkman J, Cotran R. Relation of vascular proliferation to tumour growth. Int Rev Exp Pathol. 16:1976;207-248.
90. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 66:1993;181-196.
91. Fan T-PD, Jaggar RT, Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci. 16:1995;57-66.
92. Fontanini G, Bigini D, Vignati S. Microvessel count predicts metastatic disease and survival in non-small cell lung carcinoma. J Pathol. 177:1995;57-63.
93. Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumour cells, tumour vessels and pulmonary metastases following tumour implantation. Cancer Res. 39:1974;997-1004.
94. Liotta L, Saidel G, Kleinerman J. The significance of haematogenous tumour cell clumps in the metastatic process. Cancer Res. 36:1976;889-894.
95. Fox SB, Leek RD, Bliss J. Association of tumour angiogenesis with bone marrow microÍmetastases in breast cancer patients. J Natl Cancer Inst. 89:1997;1044-1048.
96. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastases: correlation in invasive breast cancer. N Engl J Med. 324:1991;1-8.
97. Weidner N, Carroll PR, Flax J, Flumenfeld W, Folkman J. Tumour angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143:1993;401-409.
98. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Meriono MJ. Tumour angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 147:1995;33-41.
99. Maeda K, Chung YS, Takatsuka S. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer. 72:1995;319-323.
100. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal type gastric cancer. Clin Cancer Res. 2:1996;1679-1684.
101. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor, and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res. 55:1995;3964-3968.
102. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularisation as a prognostic factor in thin (<0.76 mm) malignant melanomas. Am J Pathol. 145:1994;510-514.
103. Srivastava A, Laidler P, Daives RP. The prognostic significance of tumour vascularity in intermediate thickness (0.76-4.0 mm) skin melanoma: a quantitative histologic study. Am J Pathol. 133:1988;419-423.
104. Costello P, McCann A, Carney DN, Dervan PA. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol. 26:1995;1181-1184.
105. Van Hoef ME, Knox WF, Dhesi SS, Howell A, Schor AM. Assessment of tumour vascularity as a prognostic factor in lymph node negative breast cancer. Eur J Cancer. 29A:1993;1141-1145.
106. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long term survival for patients with node negative breast cancer. J Natl Cancer Inst. 88:1996;1764-1769.
107. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadinna G. Local recurrences following mastectomy: support for the concept of tumour dormancy. J Natl Cancer Inst. 85:1994;45-48.
108. Crowley NNJ, Seigler HF. Relationship between disease free interval and survival in patients with recurrent melanoma. Arch Surg. 127:1992;1303-1308.
109. Holmgren L, O'Reilly MS, Folkman J. Dormancy of microÍmetastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1:1995;149-153.
110. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumours in mice. Nature Med. 2:1996;689-692.
111. O'Reilly MS, Holmgren L, Shing Y. Angiotensin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
112. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:1995;3964-3968.
113. Pezzella F, Di Bacco A, Andreola S, Nicholson AG, Pastorino U, Harris AL. Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer. 32A:1996;2494-2500.
114. Folkman J. Tumour angiogenesis and tissue factor. Nat Med. 2:1996;167-168.
115. Nicosia RF, Tchao R, Leighton J. Angiogenesis dependent tumour spread in reinforced fibrin clot culture. Cancer Res. 43:1983;2159-2166.
116. Hamada J, Cavanagh PG, Lotan O, Nicolson GL. Separable growth and migration factors for large cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer. 66:1992;349-354.
117. McNamara DA, Harmey JH, Walsh TN, Redmond HP, Bouchier-Hayes DJ. Significance of angiogenesis in cancer therapy. Br J Surg. 85:1998;1044-1055.
118. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 217:1992;10931-10934.
119. Evans R. Effect of X-irradiation on host cell infiltration and growth of a murin fibrosarcoma. Br J Cancer. 35:1977;557-566.
120. Mostafa LK, Jones DB, Wright DH. Mechanism of the induction of angiogenesis by human neoplastic lymphoid tissue: studies on the chorioallantoic membrane (C.A.M.) of the chick embryo. J Pathol. 132:1980;191-205.
121. Mostafa LK, Jones DB, Wright H. Mechanism of the induction of angiogenesis by human neoplastic lymphoid tissue: studies employing bovine aortic endothelial cells in vitro. J Pathol. 132:1980;207-216.
122. Van Netten JP, Ashmed BJ, Cavers D, Fletcher S, Thornton IG, Antonsen BL. Macrophages and their putative significance in human breast cancer. Br J Cancer. 66:1992;220-221.
123. Polverini PJ, Cotran RS, Gimbrone Jr. MA, Unanue ER. Activated macrophages induce vascular proliferation. Nature. 269:1977;804-806.
124. Ingber D. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem. 47:1991;236-241.
125. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis. Cell. 58:1989;803-805.
126. Bornstein P. Diversity of function is inherent in matrix proteins: an appraisal of thrombospondin-1. J Cell Biol. 130:1995;503-506.
127. Dipietro LA, Nissen NN, Gamelli RL, Koch AE, Pyle JM, Polverini PJ. Thrombospondin-1: Synthesis and function in wound repair. Am J Pathol. 148:1996;1851-1860.
128. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol. 55:1994;410-422.
129. Pugh-Humphreys RG. Macrophage-neoplastic cell inter- actions: implications for neoplastic cell growth. FEMS Microbiol Immunol. 5:1992;289-308.
130. McNamara DA, Pidgeon G, Harmey JH, Redmond HP, Walsh TN, Bouchier-Hayes DJ. LPS mediated up-regulation of VEGF in macrophages and tumour cells. Br J Surg. 85:1998;714.
131. Watson RW, Redmond HP, McCarthy J, Burke PE, Bouchier-Hayes D. Exposure of the peritoneal cavity to air regulates early inflammatory responses to surgery in a murine model. Br J Surg. 82:1995;1060-1065.
132. Ingber DE. Extracellular matrix as a solid state regulator in angiogenesis: identification of new targets for anti cancer therapy. Cancer Biol. 3:1992;57-63.
133. Ingber DE, Folkman J. Inhibition of angiogenesis through inhibition of collagen metabolism. Lab Invest. 59:1988;44-54.
134. D'Errico A, Garbisa S, Liotta L. Augmentation of type IV collagenase laminin receptor - ki67 proliferation antigen association with human colon gastric and breast cancer progression. Mol Pathol. 4:1991;239-246.
135. Grigoni WF, D'Errico A, Fortunato C. Prognosis of gastric carcinoma revealed by interactions between tumour cells and basement membrane. Mod Pathol. 7:1994;220-225.
136. Mori M, Barnard GF, Mimori K. Overexpression of MMP-7 mRNA in human colorectal carcinomas. Cancer. 75 (Suppl. 6):1995;1516-1519.
137. Satoh K, Ohtari H, Shimosegawa T. Infrequent stomach expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas. Gastronterology. 107:1994;1488-1498.
138. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA. Interstitial collagenase is required for angiogenesis in vitro. Dev Biol. 162:1994;499-510.
139. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol. 6:1995;967-974.
140. Anderson IC, Shipp MA, Docherty AJP, Teicher BA. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. 56:1996;715.
141. Johnson MD, Kim H-RC, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol. 160:1994;194-202.
142. Nelson NJ. Inhibitors of angiogenesis enter phase III testing. J Natl Cancer Inst. 90:1998;960-963.
143. Bussolino F, Mantovani A, Persico G. Molecular mechanism of blood vessel formation. Trends Biochem Sci. 22:1997;251-256.
144. O'Reilly MS, Boehm T, Shing Y. Endostatin: An endogenous inhibitor of angiogenesis and tumour growth. Cell. 88:1997;277-285.
145. Ingber D, Fujita T, Kishimoto S. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 348:1990;555-557.
146. Abe JI, Zhou W, Takawu N, Taguchi JI, Kurokawa K, Kumada M, Takawu Y. A fumagillin derivative angiogenesis inhibitor, AGM 1470, inhibits activation of cyclin dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or proto-oncogene expression in vascular endothelial cells. Cancer Res. 54:1994;3407-3412.
147. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L. Genistein, a dietary derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA. 90:1993;2690-2694.
148. Gagliardi A, Hadd H, Collins DC. Inhibition of angiogenesis by suramin. Cancer Res. 52:1992;5073-5075.
149. 3for angiogenesis. Science. 264:1994;569-571.
150. 3antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
151. 3blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 96:1995;1815-1822.
152. Evan GI, Wylie AH, Gilbert CS. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128.
153. Dedera DA, Waller KE, LeBrun DP, Sen-Majumdar A, Stevens ME, Barsh GS, Cleary ML. Chineric homeobox gene E2A-PBX1 induces proliferation, apoptosis and malignant lymphomas in transgenic mice. Cell. 74:1993;833-843.
154. Harrington EA, Fanidi A, Evan GI. Oncogenes and cell death. Curr Opin Gen Dev. 4:1994;120-129.
155. Hockenberry DM, Zuter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks cell death. Nature. 348:1990;334-336.
156. Libermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53 dependent and independent pathways. Oncogene. 11:1995;199-210.
157. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 370:1996;88-91.
158. Minchenko A, Salaceda S, Bauer T, Caro J. Hypoxia regulates elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res. 40:1994;35-39.
159. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 270:1995;13 333-40.
160. Teicher B, Holden S, Ara G, Korbut T, Menon K. Comparison of several anti-angiogenic regimes along and with cytotoxic treatment in Lewis lung carcinoma. Cancer Chemother Pharmacol. 38:1996;969-977.
161. Teicher BA, Alvarez-Sotomayor E, Huang ZD. Anti- angiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52:1992;6702-6704.
162. Teicher BA, Emi Y, Kakeji Y, Northey D. TNP-470/Minocycline cytotoxic chemotherapy: a systematic approach to cancer chemotherapy. Eur J Cancer. 32(A):1996;2461-2466.
163. Burrows FJ, Thorpe PE. Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasculature. Proc Natl Acad Sci USA. 90:1993;8996-9000.
164. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer. 49:1984;405-413.
165. Boehm T, Folkman J, Browder T, O'Reilly MS. Anti- angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
166. Kerbel RS. A cancer therapy resistant to resistance. Nature. 390:1997;335-336.
167. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science. 261:1993;209-211.
168. Lemarchand P, Ari Jaffe H, Danel C. Adenovirus mediated transfer of a recombinant human alpha-1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci USA. 89:1992;6482-6486.
169. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res. 72:1993;1132-1138.
170. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 143:1993;1255-1262.
171. Plate GH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis - coordinate induction of VEGF receptors, distribution of VEGF and possible in vivo regulatory mechanisms. Int J Cancer. 59:1994;520-529.
172. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig N. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 3:1997;1222-1227.
173. Thorban S, Roder JD, Pantel K, Siewert JR. Immuno- cytochemical detection of isolated epithelial tumour cells in bone marrow of patients with pancreatic carcinoma. Am J Surg. 172:1996;297-298.
174. Thoran S, Roder JD, Nekarda H. Immunocytochemical detection of disseminated tumour cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst. 88:1996;1222-1227.